FDA's Amy Abernethy tells the Pink Sheet that initial priorities are likely to include studying COVID-19 natural history and how patients are faring under various medication regimens. Aetion's ability to perform consistent analyses across a variety of data sets was key for FDA in selecting the partnership, which grew from Reagan-Udall Foundation and Friends of Cancer Research's Evidence Accelerator project.
Read More
Read More